Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terpene-Enriched CBD Oil in Children with ADHD
NCT06542445Phase 2Recruiting
- Sponsor
- Bazelet Nehushtan
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing CBD oil enriched with terpenes with Placebo oil (2 arms). Primary endpoints: Conners' Parent Questionnaire - Hyperactivity sub-score at 5 weeks and Conners' Parent Questionnaire - Inattentiveness sub-score at 5 weeks. Started Aug 2024; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06542445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06542445.